Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4765686 | 0.95 | SLC6A3 (0.44) | SLC6A3SLC6A4SLC6A2MAPTMEN1 | |
| SCHEMBL4724130 | 0.86 | SLC6A3 (0.48) | SLC6A3SLC6A4SLC6A2MAPTMEN1 | |
| SCHEMBL4723127 | 0.83 | SLC6A3 (0.46) | SLC6A3SLC6A4SLC6A2MAPTMEN1 | |
| SCHEMBL4722937 | 0.81 | SLC6A3 (0.44) | SLC6A3SLC6A4SLC6A2NPSR1GAA | |
| SCHEMBL4724570 | 0.81 | SLC6A3 (0.46) | SLC6A3SLC6A4SLC6A2MAPTMEN1 | |
| SCHEMBL4722969 | 0.79 | SLC6A3 (0.44) | SLC6A3SLC6A4SLC6A2MAPTMEN1 | |
| SCHEMBL4720972 | 0.77 | SLC6A3 (0.36) | SLC6A3SLC6A4SLC6A2MAPTMEN1 | |
| SCHEMBL4765357 | 0.77 | SLC6A3 (0.39) | SLC6A3SLC6A4SLC6A2MAPTMEN1 | |
| SCHEMBL4721787 | 0.77 | SLC6A3 (0.36) | SLC6A3SLC6A4SLC6A2MAPTMEN1 | |
| SCHEMBL4721684 | 0.77 | SLC6A3 (0.42) | SLC6A3SLC6A4SLC6A2NPSR1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | PFIZER INC. | 2008-07-24 | — | — | US | disclosed |
| EP-1874780-A1 | 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | Pharmacia & Upjohn Company LLC (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006100591-A1 | 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | TBXA2R, P2RY4, PF4 | SLC6A3 2115/4885SLC6A4 533/4885SLC6A2 3030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.